Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. It is principally associated with liver cirrhosis and chronic liver disease. The major risk factors for the development of HCC include viral infections (HBV, HCV), alcoholic liver disease (ALD,) and non-alcoholic fatty liver...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/12/3/436 |
| _version_ | 1797446383498690560 |
|---|---|
| author | Evgenia Kotsifa Chrysovalantis Vergadis Michael Vailas Nikolaos Machairas Stylianos Kykalos Christos Damaskos Nikolaos Garmpis Georgios D. Lianos Dimitrios Schizas |
| author_facet | Evgenia Kotsifa Chrysovalantis Vergadis Michael Vailas Nikolaos Machairas Stylianos Kykalos Christos Damaskos Nikolaos Garmpis Georgios D. Lianos Dimitrios Schizas |
| author_sort | Evgenia Kotsifa |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. It is principally associated with liver cirrhosis and chronic liver disease. The major risk factors for the development of HCC include viral infections (HBV, HCV), alcoholic liver disease (ALD,) and non-alcoholic fatty liver disease (NAFLD). The optimal treatment choice is dictated by multiple variables such as tumor burden, liver function, and patient’s health status. Surgical resection, transplantation, ablation, transarterial chemoembolization (TACE), and systemic therapy are potentially useful treatment strategies. TACE is considered the first-line treatment for patients with intermediate stage HCC. The purpose of this review was to assess the indications, the optimal treatment schedule, the technical factors associated with TACE, and the overall application of TACE as a personalized treatment for HCC. |
| first_indexed | 2024-03-09T13:39:46Z |
| format | Article |
| id | doaj.art-ce1f549d321d441783ae933680573656 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-09T13:39:46Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-ce1f549d321d441783ae9336805736562023-11-30T21:08:27ZengMDPI AGJournal of Personalized Medicine2075-44262022-03-0112343610.3390/jpm12030436Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?Evgenia Kotsifa0Chrysovalantis Vergadis1Michael Vailas2Nikolaos Machairas3Stylianos Kykalos4Christos Damaskos5Nikolaos Garmpis6Georgios D. Lianos7Dimitrios Schizas8Second Propaedeutic Department of Surgery, National and Kapodistrian University of Athens, General Hospital of Athens “Laiko”, AgiouThoma 17, 11527 Athens, GreeceDepartment of Radiology, General Hospital of Athens “Laiko”, AgiouThoma 17, 11527 Athens, GreeceFirst Department of Surgery, National and Kapodistrian University of Athens, General Hospital of Athens “Laiko”, AgiouThoma 17, 11527 Athens, GreeceSecond Propaedeutic Department of Surgery, National and Kapodistrian University of Athens, General Hospital of Athens “Laiko”, AgiouThoma 17, 11527 Athens, GreeceSecond Propaedeutic Department of Surgery, National and Kapodistrian University of Athens, General Hospital of Athens “Laiko”, AgiouThoma 17, 11527 Athens, GreeceSecond Propaedeutic Department of Surgery, National and Kapodistrian University of Athens, General Hospital of Athens “Laiko”, AgiouThoma 17, 11527 Athens, GreeceSecond Propaedeutic Department of Surgery, National and Kapodistrian University of Athens, General Hospital of Athens “Laiko”, AgiouThoma 17, 11527 Athens, GreeceDepartment of Surgery, University Hospital of Ioannina, 45110 Ioannina, GreeceFirst Department of Surgery, National and Kapodistrian University of Athens, General Hospital of Athens “Laiko”, AgiouThoma 17, 11527 Athens, GreeceHepatocellular carcinoma (HCC) is the most common primary liver malignancy. It is principally associated with liver cirrhosis and chronic liver disease. The major risk factors for the development of HCC include viral infections (HBV, HCV), alcoholic liver disease (ALD,) and non-alcoholic fatty liver disease (NAFLD). The optimal treatment choice is dictated by multiple variables such as tumor burden, liver function, and patient’s health status. Surgical resection, transplantation, ablation, transarterial chemoembolization (TACE), and systemic therapy are potentially useful treatment strategies. TACE is considered the first-line treatment for patients with intermediate stage HCC. The purpose of this review was to assess the indications, the optimal treatment schedule, the technical factors associated with TACE, and the overall application of TACE as a personalized treatment for HCC.https://www.mdpi.com/2075-4426/12/3/436hepatocellular carcinomatransarterial chemoembolizationcirrhosisliverneoplasm |
| spellingShingle | Evgenia Kotsifa Chrysovalantis Vergadis Michael Vailas Nikolaos Machairas Stylianos Kykalos Christos Damaskos Nikolaos Garmpis Georgios D. Lianos Dimitrios Schizas Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? Journal of Personalized Medicine hepatocellular carcinoma transarterial chemoembolization cirrhosis liverneoplasm |
| title | Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? |
| title_full | Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? |
| title_fullStr | Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? |
| title_full_unstemmed | Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? |
| title_short | Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? |
| title_sort | transarterial chemoembolization for hepatocellular carcinoma why when how |
| topic | hepatocellular carcinoma transarterial chemoembolization cirrhosis liverneoplasm |
| url | https://www.mdpi.com/2075-4426/12/3/436 |
| work_keys_str_mv | AT evgeniakotsifa transarterialchemoembolizationforhepatocellularcarcinomawhywhenhow AT chrysovalantisvergadis transarterialchemoembolizationforhepatocellularcarcinomawhywhenhow AT michaelvailas transarterialchemoembolizationforhepatocellularcarcinomawhywhenhow AT nikolaosmachairas transarterialchemoembolizationforhepatocellularcarcinomawhywhenhow AT stylianoskykalos transarterialchemoembolizationforhepatocellularcarcinomawhywhenhow AT christosdamaskos transarterialchemoembolizationforhepatocellularcarcinomawhywhenhow AT nikolaosgarmpis transarterialchemoembolizationforhepatocellularcarcinomawhywhenhow AT georgiosdlianos transarterialchemoembolizationforhepatocellularcarcinomawhywhenhow AT dimitriosschizas transarterialchemoembolizationforhepatocellularcarcinomawhywhenhow |